Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

被引:262
|
作者
Zhu, Xinxin [1 ]
Lang, Jinghe [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
soluble; PD-1; PD-L1; tumor immunity; biomarker; CELL LUNG-CANCER; DEATH-LIGAND; PROGRAMMED DEATH-1; ANTITUMOR IMMUNITY; T-CELLS; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS; PD-1/PD-L1; BLOCKADE; CIRCULATING PD-L1;
D O I
10.18632/oncotarget.18311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms. These soluble forms increase the complexity and diversity of the composition and function of the PD-1/PD-L1 signaling pathway. However, the exact roles of these molecules remain unknown. The objective of this systematic review was to elucidate the biological significance of soluble PD-1/PD-L1 in human cancers and evaluate whether they are potential diagnostic, therapeutic, or prognostic biomarkers. We expect to provide new clues for future research on soluble PD-1/PD-L1 pathway in human malignant tumors.
引用
收藏
页码:97671 / 97682
页数:12
相关论文
共 50 条
  • [31] PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Hamanishi, Junzo
    Mandai, Masaki
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Konishi, Ikuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (03) : 462 - 473
  • [32] Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
    Cheng, Chao
    Zhuge, Lingdun
    Xiao, Xin
    Luan, Siyuan
    Yuan, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
    Xu, Yichi
    Song, Gendi
    Xie, Shangdan
    Jiang, Wenxiao
    Chen, Xin
    Chu, Man
    Hu, Xiaoli
    Wang, Zhi-Wei
    MOLECULAR THERAPY, 2021, 29 (06) : 1958 - 1969
  • [34] Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
    Sun, Jin-Yu
    Zhang, Dengke
    Wu, Songquan
    Xu, Min
    Zhou, Xiao
    Lu, Xiao-Jie
    Ji, Jiansong
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [35] PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
    Bocanegra, Ana
    Fernandez-Hinojal, Gonzalo
    Zuazo-Ibarra, Miren
    Arasanz, Hugo
    Jesus Garcia-Granda, Maria
    Hernandez, Carlos
    Ibanez, Maria
    Hernandez-Marin, Berta
    Martinez-Aguillo, Maite
    Jose Lecumberri, Maria
    Fernandez de Lascoiti, Angela
    Teijeira, Lucia
    Morilla, Idoia
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07):
  • [36] Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
    Khan, Muhammad
    Zhao, Zhihong
    Arooj, Sumbal
    Fu, Yuxiang
    Liao, Guixiang
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [37] Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer A Meta-Analysis
    Zhang, Yaxiong
    Kang, Shiyang
    Shen, Jianfei
    He, Jiaxi
    Jiang, Long
    Wang, Wei
    Guo, Zhihua
    Peng, Guilin
    Chen, Gang
    He, Jianxing
    Liang, Wenhua
    MEDICINE, 2015, 94 (06) : e515
  • [38] PD-1/PD-L1 axis in organ fibrosis
    Zhao, Youliang
    Qu, Yaqian
    Hao, Changfu
    Yao, Wu
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [39] Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer
    Zhang, Ying
    Li, Jing
    Yang, Fan
    Zhang, Xiying
    Ren, Xiubao
    Wei, Feng
    JOURNAL OF LEUKOCYTE BIOLOGY, 2022, 112 (06) : 1591 - 1603
  • [40] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 818 - 830